Alex Zhavoronkov
Alex Zhavoronkov is a prominent scientist and entrepreneur known for his work in artificial intelligence and biotechnology, particularly in the fields of drug discovery and aging research. He is the founder and CEO of Insilico Medicine, a company that utilizes advanced AI technologies for drug development and biomarker discovery.
Zhavoronkov was born in Riga, Latvia, during the Soviet era. He moved to Canada, where he earned two bachelor's degrees from Queen's University in computer science and management of information systems. He later obtained a master's degree in biotechnology from Johns Hopkins University and a Ph.D. in biophysics from Moscow State University.
Zhavoronkov is recognized for pioneering applications of generative adversarial networks (GANs) and deep learning in predicting biological age and advancing the understanding of aging processes.
He is actively involved in various scientific communities and serves on editorial boards for multiple journals related to aging and molecular medicine.
Updates from Alex Zhavoronkov
2024 marked a pivotal year for longevity research, with breakthroughs spanning molecular biology and clinical applications. Highlights include 4B Technologies’ AI-discovered ALS drug entering clinical trials, Caristo Diagnostics’ AI tool predicting heart attacks a decade ahead through coronary inflammation analysis, and FDA-approved drugs showing promise in reducing mortality. Additionally, BioXtek developed regenerative therapies using human birth tissue.